{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:13:53Z","timestamp":1788671633403,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848082001"],"award-info":[{"award-number":["848082001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10234-y","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:26:15Z","timestamp":1788668775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Dose Naltrexone in Crohn\u2019s Disease: A Prematurely Terminated Randomized Trial Showing Reduced Fatigue Without Clinical or Endoscopic Benefit"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4699-6662","authenticated-orcid":false,"given":"N.","family":"van de Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Paulides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. H. J.","family":"Wolfhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. L.","family":"Holster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Fuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"10234_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MOG.0000000000000849","volume":"38","author":"M Gergely","year":"2022","unstructured":"Gergely M, Prado E, Deepak P. Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 2022;38:347\u2013357.","journal-title":"Curr Opin Gastroenterol"},{"key":"10234_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241\u2013258.","journal-title":"Am J Gastroenterol"},{"key":"10234_CR3","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn\u2019s disease. The Lancet 2017;389:1741\u20131755.","journal-title":"The Lancet"},{"key":"10234_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/15476910802131469","volume":"5","author":"GL Matters","year":"2008","unstructured":"Matters GL, Harms JF, McGovern C, Fitzpatrick L, Parikh A, Nilo N, Smith JP. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol 2008;5:179\u2013187.","journal-title":"J Immunotoxicol"},{"key":"10234_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.npep.2016.06.003","volume":"59","author":"DI Tawfik","year":"2016","unstructured":"Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn\u2019s disease in rats. Neuropeptides 2016;59:39\u201345.","journal-title":"Neuropeptides"},{"key":"10234_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","volume":"16","author":"M Lie","year":"2018","unstructured":"Lie M, van der Giessen J, Fuhler GM, de Lima A, Peppelenbosch MP, van der Ent C, van der Woude CJ. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16:55.","journal-title":"J Transl Med"},{"key":"10234_CR7","first-page":"171","volume":"14","author":"J Ploesser","year":"2010","unstructured":"Ploesser J, Weinstock LB, Thomas E. Low dose naltrexone: side effects and efficacy in gastrointestinal disorders. Int J Pharm Compd 2010;14:171\u2013173.","journal-title":"Int J Pharm Compd"},{"key":"10234_CR8","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","volume":"56","author":"JP Smith","year":"2011","unstructured":"Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial. Dig Dis Sci 2011;56:2088\u20132097.","journal-title":"Dig Dis Sci"},{"key":"10234_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol 2007;102:820\u2013828.","journal-title":"Am J Gastroenterol"},{"key":"10234_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1186\/s13063-021-05776-7","volume":"22","author":"KD Bruun","year":"2021","unstructured":"Bruun KD, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Holsgaard-Larsen A, Christensen R, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials 2021;22:804.","journal-title":"Trials"},{"key":"10234_CR11","first-page":"205521731667224","volume":"2","author":"MD Ludwig","year":"2016","unstructured":"Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Mult Scler J Exp Transl Clin 2016;2:2055217316672242.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10234_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/ecco-jcc\/jjy008","volume":"12","author":"G Raknes","year":"2018","unstructured":"Raknes G, Simonsen P, Sm\u00e5brekke L. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. J Crohns Colitis 2018;12:677\u2013686.","journal-title":"J Crohns Colitis"},{"key":"10234_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"J Younger","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014;33:451\u2013459.","journal-title":"Clin Rheumatol"},{"key":"10234_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058358","volume":"12","author":"E Paulides","year":"2022","unstructured":"Paulides E, Lie M, van der Woude CJ. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn\u2019s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study. BMJ Open 2022;12:e058358.","journal-title":"BMJ Open"},{"key":"10234_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc 2004;60:505\u2013512.","journal-title":"Gastrointest Endosc"},{"key":"10234_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet 1980;1:514.","journal-title":"Lancet"},{"key":"10234_CR17","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571\u20138.","journal-title":"Am J Gastroenterol"},{"key":"10234_CR18","first-page":"S576","volume":"11","author":"D Bojic","year":"2017","unstructured":"Bojic D, Bodger K, Travis S. Patient reported outcome measures (proms) in inflammatory bowel disease: new data. J Crohns Colitis 2017;11:S576\u2013S85.","journal-title":"J Crohns Colitis"},{"key":"10234_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"10234_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353\u2013365.","journal-title":"Pharmacoeconomics"},{"key":"10234_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63\u201374.","journal-title":"J Pain Symptom Manage"},{"key":"10234_CR22","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11136-013-0611-6","volume":"23","author":"CB Terwee","year":"2014","unstructured":"Terwee CB, Roorda LD, de Vet HC, Dekker J, Westhovens R, van Leeuwen J et al. Dutch-flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2014;23:1733\u20131741.","journal-title":"Qual Life Res"},{"key":"10234_CR23","first-page":"CD010410","volume":"4","author":"CE Parker","year":"2018","unstructured":"Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2018;4:CD010410.","journal-title":"Cochrane Database Syst Rev"},{"key":"10234_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/MCG.0000000000000093","volume":"48","author":"LB Weinstock","year":"2014","unstructured":"Weinstock LB. Naltrexone therapy for Crohn\u2019s disease and ulcerative colitis. J Clin Gastroenterol 2014;48:742.","journal-title":"J Clin Gastroenterol"},{"key":"10234_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medsci6040082","volume":"6","author":"K Toljan","year":"2018","unstructured":"Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel) 2018;6:82.","journal-title":"Med Sci (Basel)"},{"key":"10234_CR26","doi-asserted-by":"publisher","first-page":"e0187423","DOI":"10.1371\/journal.pone.0187423","volume":"12","author":"G Raknes","year":"2017","unstructured":"Raknes G, Sm\u00e5brekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. a quasi-experimental study. PLoS One 2017;12:e0187423.","journal-title":"PLoS One"},{"key":"10234_CR27","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","volume":"34","author":"A Tinsley","year":"2011","unstructured":"Tinsley A, Macklin EA, Korzenik JR, Sands BE. Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:1328\u20131336.","journal-title":"Aliment Pharmacol Ther"},{"key":"10234_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","volume":"16","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol 2019;16:247\u2013259.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10234-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:26:17Z","timestamp":1788668777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10234-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":28,"alternative-id":["10234"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10234-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ACV has served on the advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, Abbvie, Lilly, and Pfizer, outside the submitted work; GF has received speaker fees from Abbvie and Jansen; RW received speaker fees from\u00a0Ferring, Pfizer and Janssen. All other authors declare no conflicts of interest for the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}